Literature DB >> 21968298

Novel vaccines against influenza viruses.

S M Kang1, J M Song, R W Compans.   

Abstract

Killed and live attenuated influenza virus vaccines are effective in preventing and curbing the spread of influenza epidemics when the strains present in the vaccines are closely matched with the predicted epidemic strains. These vaccines are primarily targeted to induce immunity to the variable major target antigen, hemagglutinin (HA) of influenza virus. However, current vaccines are not effective in preventing the emergence of new pandemic or highly virulent viruses. New approaches are being investigated to develop universal influenza virus vaccines as well as to apply more effective vaccine delivery methods. Conserved vaccine targets including the influenza M2 ion channel protein and HA stalk domains are being developed using recombinant technologies to improve the level of cross protection. In addition, recent studies provide evidence that vaccine supplements can provide avenues to further improve current vaccies.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21968298      PMCID: PMC3401575          DOI: 10.1016/j.virusres.2011.09.037

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  112 in total

Review 1.  Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.

Authors:  Brian R Murphy; Kathleen Coelingh
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

2.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Mark Eid; Darya Zharikova; Walter Gerhard
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

3.  PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA B.

Authors:  J E Salk; H E Pearson; P N Brown; T Francis
Journal:  J Clin Invest       Date:  1945-07       Impact factor: 14.808

4.  RESULTS OF IMMUNIZATION BY MEANS OF ACTIVE VIRUS OF HUMAN INFLUENZA.

Authors:  J Stokes; A D Chenoweth; A D Waltz; R G Gladen; D Shaw
Journal:  J Clin Invest       Date:  1937-03       Impact factor: 14.808

5.  The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Takeshi Noda; Maki Kiso; Junko Maeda; Shinji Watanabe; Yukiko Muramoto; Ken Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Authors:  R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

7.  Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier.

Authors:  Roxana M Ionescu; Craig T Przysiecki; Xiaoping Liang; Victor M Garsky; Jiang Fan; Bei Wang; Robert Troutman; Yvette Rippeon; Elizabeth Flanagan; John Shiver; Li Shi
Journal:  J Pharm Sci       Date:  2006-01       Impact factor: 3.534

8.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line.

Authors:  C H Heusser; C L Anderson; H M Grey
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

10.  Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.

Authors:  Krystyna Mozdzanowska; Darya Zharikova; Mare Cudic; Laszlo Otvos; Walter Gerhard
Journal:  Virol J       Date:  2007-10-31       Impact factor: 4.099

View more
  15 in total

Review 1.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

2.  Mission of randomness.

Authors:  Guo-Ping Zhou
Journal:  Virulence       Date:  2013-11-12       Impact factor: 5.882

3.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

4.  Nanofilaments on glioblastoma exosomes revealed by peak force microscopy.

Authors:  Shivani Sharma; Kingshuk Das; JungReem Woo; James K Gimzewski
Journal:  J R Soc Interface       Date:  2014-01-08       Impact factor: 4.118

5.  A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.

Authors:  Pierre-Louis Hervé; Mariam Raliou; Christiane Bourdieu; Catherine Dubuquoy; Agnès Petit-Camurdan; Nicolas Bertho; Jean-François Eléouët; Christophe Chevalier; Sabine Riffault
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

6.  Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch.

Authors:  Fu-Shi Quan; Yeu-Chun Kim; Jae-Min Song; Hye Suk Hwang; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Clin Vaccine Immunol       Date:  2013-07-17

7.  In Silico Analysis of HA2/Mx Chimera Peptide for Developing an Adjuvanted Vaccine to Induce Immune Responses Against Influenza Viruses.

Authors:  Sina Soleimani; Omid Madadgar; Shahla Shahsavandi; Homayoon Mahravani; Mohsen Lotfi
Journal:  Adv Pharm Bull       Date:  2015-12-31

8.  Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.

Authors:  Nedzad Music; Adrian J Reber; Min-Chul Kim; Ian A York; Sang-Moo Kang
Journal:  Vaccine       Date:  2015-12-19       Impact factor: 3.641

9.  MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response.

Authors:  James S Testa; Vivekananda Shetty; Julie Hafner; Zacharie Nickens; Shivali Kamal; Gomathinayagam Sinnathamby; Ramila Philip
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Protection of Chinese painted quails (Coturnix chinensis) against a highly pathogenic H5N1 avian influenza virus strain after vaccination.

Authors:  Julia Sarkadi; Mate Jankovics; Zoltan Kis; Jozsef Skare; Kinga Fodor; Eva Gonczol; Ildiko Visontai; Zoltan Vajo; Istvan Jankovics
Journal:  Arch Virol       Date:  2013-06-15       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.